Sponsored Links
| Palatin Technologies, Inc. Announces Positive Safety Results In Subcutaneous Bremelanotide Trial In Men |
 |
 |
 |
| Medical News - Erectile Dysfunction | |||
|
Palatin Technologies, Inc. (NYSE Amex: PTN) announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD)... Read more: Erectile Dysfunction / Premature Ejaculation News From Medical News Today
|